Drugs / Iron Folic Acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT07540130 Comparator | Feb 2025 → May 2026 overdue | — | National Institute of Neurosciences and Hospital, Dhaka | Active not recruiting | No outcome recorded |
| — | NCT06327646 Comparator | Jul 2024 → Jul 2025 overdue | — | Helen Keller International | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iron Folic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07540130 ↗ |
| Known as | IFA | “iron-folic acid (IFA) supplementation” PMID 31134641 ↗ May 2019 |
| Route | Oral | “IFAS consists of a daily tablet containing 60 mg elemental iron and 400 μg folic acid, in line with national antenatal care guidelines.” NCT07540130 ↗ |